← All trials
NCT00006305
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2000
- Primary completion
- Nov 1, 2008
- Completion date
- Mar 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 2368
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of PittsburghLead sponsor
- St. Louis UniversityOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- University of VermontOverall official - principal investigator
- Mayo ClinicStudy chair
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of PittsburghReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.